Last reviewed · How we verify

NCT07298577: STOPHCC-GAAD

Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer

Not yet recruiting NA Last updated 23 December 2025
What this trial tests

NA trial testing PIVKA-II and GAAD score calculation in Liver Cirrhosis in 2,100 participants. Not yet recruiting.

Timeline
2 January 2026
Primary endpoint
31 December 2029
30 June 2030

Quick facts

Lead sponsorSiriraj Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment2,100
Start date2 January 2026
Primary completion31 December 2029
Estimated completion30 June 2030
Sites1 location across Thailand

Drugs / interventions tested

Conditions studied

Sponsor

Siriraj Hospital

Who can join

18 and older, any sex, with Liver Cirrhosis or Hepatitis B, Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

HCC surveillance is currently limited by underutilization and the suboptimal performance of AFP. This prospective, single-arm study investigates whether the GAAD score (Gender, Age, AFP, and PIVKA-II) enhances HCC detection when added to standard-of-care surveillance. High-risk patients will undergo US plus GAAD score testing every six months for two years. The primary analysis compares the relative true positive rate (rTPR) and relative false positive rate (rFPR) of surveillance modalities (US, AFP, GAAD) against combined strategies (US+AFP; US+GAAD), utilizing a 2.57 GAAD cut-off. Secondary endpoints include longitudinal biomarker kinetics, early-stage HCC detection rates, and the impact on downstream imaging (CT/MRI) volume. Ultimately, this study seeks to define the role of GAAD as a surveillance adjunct and inform future clinical guidelines for biomarker-enhanced HCC screening.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Liver Cirrhosis

Currently open trials in the same condition.

Other Siriraj Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07298577.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing